# Imatinib-$d_4$

| | |
|---|---|
| **Cat. No.:** | HY-15463S1 |
| **CAS No.:** | 1134803-16-9 |
| **Molecular Formula:** | $C_{29}H_{27}D_4N_7O$ |
| **Molecular Weight:** | 497.63 |
| **Target:** | Bcr-Abl; PDGFR; c-Kit; Autophagy; SARS-CoV |
| **Pathway:** | Protein Tyrosine Kinase/RTK; Autophagy; Anti-infection |

**Storage:**

| | | |
|---|---|---|
| Powder | -20°C | 3 years |
| | 4°C | 2 years |
| In solvent | -80°C | 6 months |
| | -20°C | 1 month |



## BIOLOGICAL ACTIVITY

**Description**

Imatinib-$d_4$ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

## REFERENCES

[1]. Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32.

[2]. Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9.

[3]. Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90(19):8924-8933. Published 2016 Sep 12.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA